Table 1.
Tumor cytoplasmic CSE1L expression and clinical parameters in CRC
| |
Cytoplasmic CSE1L |
Total |
P |
|
|---|---|---|---|---|
| Low (1+) | High (2+ or 3+) | |||
| Sex |
|
|
|
|
| female |
26 (50)# |
26 (50) |
52 |
0.884 |
| male |
37 (48.7) |
39 (51.3) |
76 |
|
| Grade |
|
|
|
|
| well |
2 (50) |
2 (50) |
4 |
0.138 |
| moderate |
55 (47) |
62 (53) |
117 |
|
| poor |
6 (85.7) |
1 (14.3) |
7 |
|
| T status |
|
|
|
|
| T1+T2 |
16 (76.2) |
5 (23.8) |
21 |
0.007* |
| T3+T4 |
47 (43.9) |
60 (56.1) |
107 |
|
| Lymph node metastasis |
|
|
|
|
| no |
42 (56) |
33 (44) |
75 |
0.068 |
| yes |
21 (39.6) |
32 (60.4) |
53 |
|
| Distant metastasis |
|
|
|
|
| no |
56 (50.5) |
55 (49.5) |
111 |
0.476 |
| yes |
7 (41.2) |
10 (58.8) |
17 |
|
| Stage |
|
|
|
|
| I |
16 (80) |
4 (20) |
20 |
0.018* |
| II |
22 (45.8) |
26 (54.2) |
48 |
|
| III |
20 (45.5) |
24 (54.5) |
44 |
|
| IV |
5 (31.3) |
11 (68.8) |
16 |
|
| Stage |
|
|
|
|
| I/ II |
38 (55.9) |
30 (44.1) |
68 |
0.108 |
| III/IV |
25 (41.7) |
35 (58.3) |
60 |
|
| Overall survival |
|
|
|
|
| ≤5 y |
33 (44.6) |
41 (55.4) |
74 |
0.221 |
| ≥5 y | 30 (55.6) | 24 (44.4) | 54 | |
Data are shown as number of cases (%).
* significant at <0.05.
** significant at <0.005.